RecruitingPhase 1NCT06736587

Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose, Dose-escalation Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers

Sponsor

Daewoong Pharmaceutical Co. LTD.

Enrollment

84 participants

Start Date

Dec 10, 2024

Study Type

INTERVENTIONAL

Conditions

Autoimmune Diseases

Summary

The safety and tolerability of single and multiple administration of DWP212525

Eligibility

Min Age: 19 YearsMax Age: 55 Years

Inclusion Criteria4

Healthy adult volunteers aged 19 to 55 years
Those with a body weight ≥ 50.0 kg to ≤ 90.0 kg with a body mass index (BMI) of ≥ 18.0 kg/m2 to ≤ 30.0 kg/m2
Received a sufficient explanation on this study
Eligible as subjects in the study

Exclusion Criteria4

History of diseases such as clinically significant disease of hepatobiliary
Following conditions applicable to clinically significant acute or chronic infections or the past history confirmed via an interview
Hemato-oncologic diseases, including malignant tumor diagnosis
Past history of tuberculosis infection or confirmed tuberculosis in the IGRA test and chest X-ray test

Interested in this trial?

Get notified about updates and connect with the research team.